Holyoake TL - Search Results

1

Do we need more drugs for chronic myeloid leukemia?

Holyoake TL, Helgason GV. Holyoake TL, et al. Immunol Rev. 2015 Jan;263(1):106-23. doi: 10.1111/imr.12234. Immunol Rev. 2015. PMID: 25510274 Review.

2

Contrasting effects of rh-MIP-1 alpha and TGF-beta 1 on chronic myeloid leukemia progenitors in vitro.

Holyoake TL, Freshney MG, Sproul AM, Richmond LJ, Alcorn MJ, Steward WP, Fitzsimons E, Dunlop DJ, Franklin IM, Pragnell IB. Holyoake TL, et al. Stem Cells. 1993 Oct;11 Suppl 3:122-8. doi: 10.1002/stem.5530110925. Stem Cells. 1993. PMID: 8298472

3

Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?

Drummond MW, Holyoake TL. Drummond MW, et al. Among authors: holyoake tl. Blood Rev. 2001 Jun;15(2):85-95. doi: 10.1054/blre.2001.0152. Blood Rev. 2001. PMID: 11409908 Review.

4

A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.

Jørgensen HG, Holyoake TL. Jørgensen HG, et al. Among authors: holyoake tl. Hematol Oncol. 2001 Sep;19(3):89-106. doi: 10.1002/hon.667. Hematol Oncol. 2001. PMID: 11574931 Review.

5

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Graham SM, et al. Among authors: holyoake tl. Blood. 2002 Jan 1;99(1):319-25. doi: 10.1182/blood.v99.1.319. Blood. 2002. PMID: 11756187 Free article.

6

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

Jørgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. Jørgensen HG, et al. Among authors: holyoake tl. Blood. 2002 Jan 15;99(2):713-5. doi: 10.1182/blood.v99.2.713. Blood. 2002. PMID: 11781261 Free article.

7

Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

Holyoake TL, Jiang X, Drummond MW, Eaves AC, Eaves CJ. Holyoake TL, et al. Leukemia. 2002 Apr;16(4):549-58. doi: 10.1038/sj.leu.2402444. Leukemia. 2002. PMID: 11960331 Review.

8

Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.

Drummond MW, Marin D, Clark RE, Byrne JL, Holyoake TL, Lennard A; United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party. Drummond MW, et al. Among authors: holyoake tl. Br J Haematol. 2003 Nov;123(3):479-83. doi: 10.1046/j.1365-2141.2003.04599.x. Br J Haematol. 2003. PMID: 14617010 Free article.

9

Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.

Drummond M, Lennard A, Brûmmendorf T, Holyoake T. Drummond M, et al. Leuk Lymphoma. 2004 Sep;45(9):1775-81. doi: 10.1080/10428190410001693542. Leuk Lymphoma. 2004. PMID: 15223635

10

The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000.

Harrison SJ, Johnson PR, Holyoake TL. Harrison SJ, et al. Among authors: holyoake tl. Scott Med J. 2004 Aug;49(3):87-90. doi: 10.1177/003693300404900305. Scott Med J. 2004. PMID: 15462221

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters